27th April 2025, A/Prof Chee L Khoo
We recently looked at the LDL-C levels needed to stabilise plaque progression and the LDL-C levels needed to cause plaque regression. Plaque stabilisation and regression leads to reduction in cardiovascular events. Dyslipidaemia (especially LDL-C) is also associated with cognitive impairment and dementia and reducing those numbers with statin therapy reduces the risk.…
28th February 2025, A/Prof Chee L Khoo
Every so often you come across a study where the initial and immediate impression is that there must be more to the conclusion. The latest study which connects the use of anti-depressants with further cognitive decline in patients with dementia is just one of those studies. Now, many patients who have dementia also have depression and are on anti-depressants and we don’t think twice about whether the drugs might hasten the decline in cognitive function in these patients.…
A/Prof Chee L Khoo, 23rd January 2025
We explored the benefits (or lack of) of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) back in early December 2024 when we look at the indications and criteria to initiate icosapent ethyl in patients with residual hypertriglyceridaemia for cardiovascular benefit. Now, omega-3 fatty acid (O3FA) supplements often contain a combination of EPA and DHA.…
9th November 2024, A/Prof Chee L Khoo
Metformin has been the first line treatment for patients with type diabetes for many years. It has many mechanisms of action with many more that we have yet to uncover. We know that it improves glucose control by improving insulin resistance. These days we have many other glucose lowering agents that are a lot more potent than metformin.…
13th April 2024, A/Prof Chee L Khoo
We are all used to metformin being the first line glucose lowering agent when type 2 diabetes (T2D) is diagnosed. (Well, I know some you also use metformin before diabetes is diagnosed but that’s a different story). Glucose lowering efficacy of metformin is not that terrific as we now have much stronger glucose lowering agents available.…
14th May 2023, Dr Chee L Khoo
When we think about diabetic complications, we usually think about microvascular and macrovascular complications. We don’t often think about dementia as a diabetic complication. Diabetes has consistently been associated with an increased risk of dementia and its subtypes (Alzheimer’s disease and vascular dementia (1). As many with diabetes, especially T2D, are being diagnosed at a younger age, dementia relating to diabetes will increasingly be diagnosed and diagnosed at a younger age.…
11th December 2021, Dr Chee L Khoo
Cataract is a leading cause of blindness worldwide, affecting more than 35 million people globally and causing blindness in approximately 20 million. Visual impairment is an important dementia risk. Addressing sensory loss from visual impairment that affects older adults may be a potentially modifiable risk factor for dementia in late life (1,2) Because sensory impairments and dementia are both strongly associated with aging the link between sensory impairment and dementia may have important implications for individual and global public health, particularly if interventions to improve sensory function reduce dementia risk (3).…
9th May 2021, Dr Chee L Kho
When we think of diabetes-related complications, we usually think about microvascular and macrovascular complications. We don’t usually think about dementia. Type 2 diabetes (T2D) represents an increasing health burden world-wide and its prevalence in particularly higher in elderly population. While epidemiological evidence suggests an increased risk of vascular and Alzheimer’s dementia associated with T2D, the mechanisms underlying the association, however, remain unclear.…